Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies

12 May 2022

Abstract excerpt

Metastatic castration-resistant prostate cancers (mCRPCs) are treated with therapies that antagonize the androgen receptor (AR). Nearly all patients develop resistance to AR-targeted therapies (ARTs). Our previous work identified CREB5 as an upregulated target gene in human mCRPC that promoted resistance to all clinically approved ART. The mechanisms by which CREB5 promotes progression of mCRPC or other cancers...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Prostate Cancer Treatment and Research
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35550030
DOI: 10.7554/elife.73223

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapiesPMID 35550030Read ↗

CREB5 reprograms nuclear interactions to promote resistance to androgen receptor targeting therapiesSemantic proximity Read ↗

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate CancerSemantic proximity Read ↗

Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrenceSemantic proximity Read ↗

EP300/CREBBP acetyltransferase inhibition limits steroid receptor and FOXA1 signaling in prostate cancer cellsSemantic proximity Read ↗

Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancerSemantic proximity Read ↗

Genome-wide analyses of transcription factors and co-regulators across seven cohorts identified reduced PPARGC1A expression as a driver of prostate cancer progressionSemantic proximity Read ↗

Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype.Semantic proximity Read ↗

Identification of transcription factor co-regulators that drive prostate cancer progression.Semantic proximity Read ↗

A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancerSemantic proximity Read ↗

Epigenome-wide impact of MAT2A sustains the androgen-indifferent state and confers synthetic vulnerability in ERG fusion-positive prostate cancerSemantic proximity Read ↗

Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer towards androgen-independenceSemantic proximity Read ↗

Dysregulation of splicing-related proteins in prostate cancer is controlled by FOXA1Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.